Nuvation Bio to broaden Phase III glioma trial into Europe
Nuvation Bio is set to expand its pivotal Phase III SIGMA trial into Europe to evaluate safusidenib in patients with IDH1-mutant glioma.
The post Nuvation Bio to broaden Phase III glioma trial into Europe appeared first on Clinical Trials Arena .